---
title: "Sutro Biopharma (STRO) news: reverse split and delisting"
url: "https://aibio.space/companies/sutro-biopharma/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "STRO reverse split, delisting and Nasdaq notice news: Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price. Sutro Biopharma, Inc."
---

STRO Sutro Biopharma, Inc. NASDAQ · United States

# Sutro Biopharma (STRO) news STRO reverse split, delisting and Nasdaq notice news

Distress · 2025-09-29

## [Sutro Biopharma plans to cut workforce by about one-third, expects cash runway into mid-2027](https://aibio.space/news/sutro-biopharma-plans-cut-workforce-about-one-third-expects-cash/)

Sutro Biopharma (Nasdaq: STRO) plans a workforce reduction of approximately one-third to focus on three preclinical ADC programs. It estimates $4.1 million to $4.3 million in costs.

## Latest Sutro Biopharma news

1. 2025-06-25 Listings [Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price](https://aibio.space/news/sutro-biopharma-receives-nasdaq-notice-falling-below-1-00-bid-price/) Sutro has until December 17, 2025 to bring its share price back above $1.00 for ten consecutive business days, or face a delisting process. The company says it plans a reverse stock split before that date if necessary, and its 10-K shows three partners that ended clinical work after Phase 1.
2. 2025-03-13 Distress [Sutro Biopharma to cut about 50% of workforce in restructuring, names new CEO](https://aibio.space/news/sutro-biopharma-cut-about-50-percent-workforce-restructuring-names-new/) Sutro will deprioritize luvelta, exit its manufacturing facility and cut about 50% of staff, with costs of $40 million to $45 million. Jane Chung succeeds William J. Newell as CEO. Cash was $316.9 million at year-end.

## Sutro Biopharma at a glance

- **Ticker**: STRO

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $164.3 million

### Related companies

- [Kiora Pharmaceuticals](https://aibio.space/companies/kiora-pharmaceuticals/) NASDAQ: KPRX
- [NovaBridge Biosciences](https://aibio.space/companies/novabridge-biosciences/) NASDAQ: NBP
- [Tenax Therapeutics](https://aibio.space/companies/tenax-therapeutics/) NASDAQ: TENX
- [Rezolute](https://aibio.space/companies/rezolute/) NASDAQ: RZLT
- [Regeneron Pharmaceuticals](https://aibio.space/companies/regeneron-pharmaceuticals/) NASDAQ: REGN
- [Zevra Therapeutics](https://aibio.space/companies/zevra-therapeutics/) NASDAQ: ZVRA
- [TRex Bio](https://aibio.space/companies/trex-bio/) NASDAQ: TRXB
- [Seaport Therapeutics](https://aibio.space/companies/seaport-therapeutics/) NASDAQ: SPTX

### Also on NASDAQ

- [Larimar Therapeutics](https://aibio.space/companies/larimar-therapeutics/) LRMR
- [Nkarta](https://aibio.space/companies/nkarta/) NKTX
- [Creative Medical Technology Holdings](https://aibio.space/companies/creative-medical-technology/) CELZ
- [Whitehawk Therapeutics](https://aibio.space/companies/whitehawk-therapeutics/) WHWK
- [Immunocore Holdings](https://aibio.space/companies/immunocore/) IMCR
- [Tarsus Pharmaceuticals](https://aibio.space/companies/tarsus-pharmaceuticals/) TARS

## Sutro Biopharma annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$166.4 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/) | [$252.0 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/) |
| Net income (loss) | [-$191.1 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/) | [-$227.5 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/) |
| Cash from operations | [-$177.2 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/) | [-$191.5 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/) |
| Cash and equivalents | [$58.1 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526345748/) | [$190.3 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/) |
| Short-term investments | [$83.3 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526345748/) | [$126.6 million](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $54.3 million, plus short-term investments of $110.0 million, $164.3 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Analysis

- Opinion Negative view 2026-10-28 [Sutro has about 14 months of cash at average burn, so we expect a raise](https://aibio.space/analysis/sutro-has-about-14-months-cash-average-burn-so-we-expect/) Sutro had $164.3 million at June 30, 2026, and burned $36.3 million a quarter on average. Management says that lasts at least 12 months. We think another raise comes before the cash runs out.

Opinion, not personal investment advice. [All analysis](https://aibio.space/analysis/).

## Questions about Sutro Biopharma

Did Sutro Biopharma do a reverse stock split?

Our latest story on this, dated Jun 25, 2025: "Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sutro-biopharma-receives-nasdaq-notice-falling-below-1-00-bid-price/).

Was Sutro Biopharma delisted?

Our latest story on this, dated Jun 25, 2025: "Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sutro-biopharma-receives-nasdaq-notice-falling-below-1-00-bid-price/).

Has Sutro Biopharma received a Nasdaq deficiency notice?

Our latest story on this, dated Jun 25, 2025: "Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/sutro-biopharma-receives-nasdaq-notice-falling-below-1-00-bid-price/).

What is the ticker symbol of Sutro Biopharma?

Sutro Biopharma, Inc. trades under the ticker STRO on NASDAQ.

Where is Sutro Biopharma listed?

Sutro Biopharma, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:S090.

What is the SEC CIK of Sutro Biopharma?

The SEC Central Index Key (CIK) for Sutro Biopharma, Inc. is 1382101. Its filings are on SEC EDGAR.

How many shares does Sutro Biopharma have outstanding?

16,581,171 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is Sutro Biopharma listed under?

Our directory records Sutro Biopharma, Inc. under United States.

What does Sutro Biopharma do?

Our directory classifies Sutro Biopharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Sutro Biopharma?

The ISIN recorded for Sutro Biopharma, Inc. is US8693672011.

Does aibio.space cover Sutro Biopharma?

aibio.space lists Sutro Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Is Sutro Biopharma profitable?

Sutro Biopharma, Inc. reported a net loss of $191.1 million for the fiscal year ended Dec 31, 2025, and used $177.2 million of cash in operations, per its annual report to the SEC.

How much does Sutro Biopharma spend on research and development?

$166.4 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Sutro Biopharma have?

$164.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

What is the latest Sutro Biopharma (STRO) stock news?

Our latest story on Sutro Biopharma, dated Sep 29, 2025: "Sutro Biopharma plans to cut workforce by about one-third, expects cash runway into mid-2027". Sutro Biopharma (Nasdaq: STRO) plans a workforce reduction of approximately one-third to focus on three preclinical ADC programs. It estimates $4.1 million to $4.3 million in costs. [Source](https://aibio.space/news/sutro-biopharma-plans-cut-workforce-about-one-third-expects-cash/).

## Investor discussion: Sutro Biopharma

Members talk about Sutro Biopharma (STRO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Sutro Biopharma, newest first. Each line links the filing it comes from.

1. 2026-03-23 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,2.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/stro-ex99_1.htm)
2. 2026-03-23 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1382101/000119312526120004/d115714ds3.htm)
3. 2026-02-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1382101/000119312526044923/d72308d424b5.htm)
4. 2025-12-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1382101/000119312525322859/d40412d8k.htm)
5. 2025-12-03 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1382101/000119312525306786/stro-ex99_1.htm)
6. 2025-09-29 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1382101/000119312525223434/stro-ex99_1.htm)
7. 2025-06-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1382101/000095017025089978/stro-20250620.htm)
8. 2025-06-10 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1382101/000119312525138481/d859738d8k.htm)
9. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1382101/000095017025058774/stro-20250424.htm)
10. 2025-04-14 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1382101/000095017025053739/stro-20250414.htm)
11. 2025-03-13 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1382101/000095017025038879/stro-ex99_1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:STRO on TradingView](https://www.tradingview.com/symbols/NASDAQ-STRO/).

## SEC filings and registration

- **SEC name**: Sutro Biopharma, Inc.

- **CIK**: 1382101

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: STRO (Nasdaq)

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080

- **Phone**: 650-392-8412

- **Shares outstanding**: 16,581,171 as of 2026-08-07 (10-Q filed 2026-08-12)

- **Former names**: SUTRO BIOPHARMA INC; Fundamental Applied Biology Inc

### Recent filings (8-K and 6-K are the company's own announcements)

- [10-Q](https://www.sec.gov/Archives/edgar/data/1382101/000119312526345748/stro-20260630.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/stro-20260812.htm) filed 2026-08-12
- [8-K](https://www.sec.gov/Archives/edgar/data/1382101/000119312526261658/d116098d8k.htm) filed 2026-06-08
- [10-Q](https://www.sec.gov/Archives/edgar/data/1382101/000119312526224170/stro-20260331.htm) filed 2026-05-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1382101/000119312526224065/stro-20260514.htm) filed 2026-05-14
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1382101/000119312526170354/stro-20260420.htm) filed 2026-04-22
- [S-3](https://www.sec.gov/Archives/edgar/data/1382101/000119312526120004/d115714ds3.htm) filed 2026-03-23
- [10-K](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119873/stro-20251231.htm) filed 2026-03-23

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001382101), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Sutro Biopharma, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker STRO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Sutro Biopharma, Inc.

- **Ticker**: STRO

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Pharmaceuticals: Major

- **ISIN**: US8693672011

- **Other listed symbols**: GETTEX:S090

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-STRO/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/sutro-biopharma/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Sutro Biopharma (STRO) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/sutro-biopharma/